Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
5.37M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
163K
-
Shares change
-
+83.4K
-
Total reported value, excl. options
-
$935K
-
Value change
-
+$529K
-
Number of buys
-
3
-
Number of sells
-
-4
-
Price
-
$5.76
Significant Holders of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) as of Q1 2025
10 filings reported holding NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share as of Q1 2025.
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 163K shares
of 5.37M outstanding shares and own 3.04% of the company stock.
Largest 10 shareholders include AdvisorShares Investments LLC (69.7K shares), Lynx1 Capital Management LP (45.8K shares), Prosperity Wealth Management, Inc. (27.2K shares), Merck & Co., Inc. (10K shares), Cyndeo Wealth Partners, LLC (10K shares), RHUMBLINE ADVISERS (415 shares), MORGAN STANLEY (7 shares), UBS Group AG (0 shares), BANK OF AMERICA CORP /DE/ (0 shares), and JANE STREET GROUP, LLC (0 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.